POLISCOPE
Back to feed

The civic record

Read. Follow. Verify.
High Impact

Senate Hearing on U.S. COVID-19 Response (March 3, 2020)

Original title: AN EMERGING DISEASE THREAT: HOW THE U.S. IS RESPONDING TO COVID-19, THE NOVEL CORONAVIRUS

Record date · January 1, 2021

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Does

This Senate Health, Education, Labor, and Pensions Committee hearing convened top federal health officials to provide accurate information on the emerging COVID-19 threat. The session focused on the status of the virus in the U.S., the potential impact on the global economy, and the nation's preparedness to manage the outbreak.

Why it matters

This hearing established the federal government's early public assessment of the COVID-19 threat, influencing subsequent legislative and public health actions regarding the pandemic.

Who It Affects

Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.

Directly affected

American public

The public is the primary audience for the health information and guidance provided by the federal officials during the hearing.

Directly affected

U.S. importers and manufacturers

These entities face potential supply chain disruptions due to factory shutdowns and lockdowns in China.

Key Facts

  • As of March 3, 2020, there were approximately 90,000 global COVID-19 cases across 65 countries and 3,000 deaths.
  • As of March 3, 2020, there were approximately 100 confirmed COVID-19 cases in the United States.
  • Approximately 50% of U.S. cases at the time were individuals who contracted the disease overseas and were brought back for quarantine.
  • There were six recorded deaths in the United States due to COVID-19 as of the hearing date.
Show all 7 facts
  • More than 20% of U.S. imports, including medicines and electronics, originate from China.
  • China had implemented lockdowns affecting 16 cities and 760 million people to contain the virus.
  • The hearing was held in room 430 of the Dirksen Senate Office Building.

Frequently Asked Questions

What was the purpose of this hearing?
To provide accurate information to the American public and to help members of Congress determine what further actions were needed to address the COVID-19 outbreak.
Who testified at this hearing?
The hearing featured testimony from Dr. Anne Schuchat (CDC), Dr. Anthony Fauci (NIAID), Dr. Robert Kadlec (HHS), and Dr. Stephen Hahn (FDA).

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

temporal pattern100% confidence

Early Pandemic Assessment

The hearing highlights the stark contrast between the global scale of the virus in March 2020 and the relatively low number of confirmed cases in the U.S. at that specific time.

Connected Entities

Lamar Alexander, Anne Schuchat, Stephen Hahn and 4 more
PersonLamar Alexander“Chairman of the Committee on Health, Education, Labor, and Pensions”Map →
PersonAnne Schuchat“Principal Deputy Director, Centers for Disease Control and Prevention”Map →
PersonStephen Hahn“Commissioner, U.S. Food and Drug Administration”Map →
OrganizationWorld Health Organization“Source of global case and death statistics”Map →
PersonRobert Kadlec“Assistant Secretary for Preparedness and Response, HHS”Map →
PersonPatty Murray“Ranking Member of the Committee”Map →
PersonAnthony Fauci“Director, National Institute of Allergy and Infectious Diseases”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance95
    How much this matters to a regular citizen
  • Controversy20
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz15
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record